Drugs / Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001685 | Nov 1997 → Sep 2000 | melanoma, metastatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001685 ↗ |
| Modality | Vaccine | “This is a study of a melanoma tumor antigen peptide vaccine.” NCT00001685 ↗ |
| Route | Subcutaneous | “this peptide vaccine administered subcutaneously” NCT00001685 ↗ |